News

Life Edit Will Use CFF Award to Explore Gene-editing Technology

The Cystic Fibrosis Foundation (CFF) is awarding Life Edit Therapeutics up to $400,000 to explore its new gene-editing technology to develop treatments for certain patients with cystic fibrosis (CF) who cannot benefit from existing medicines. “We’re looking forward to working with the CF Foundation to leverage the unique…

CHMP Favors Kaftrio to Treat CF Patients in EU Starting at Age 12

A European Medicines Agency (EMA) committee favors extending the label for Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to treat cystic fibrosis (CF) patients 12 and older who have at least one copy of the CFTR gene with an F508del mutation. The European Commission (EC) approved the same combination last year…

Bacterial Fatty Acids May Play Role in Exacerbations in CF Children

Due to persistent bacterial infections, long-chain fatty acids (LCFA) are linked to continued inflammation in cystic fibrosis (CF) patients — and may contribute to pulmonary exacerbations in children with CF, according to a recent study. The scientists said further studies are needed to examine how bacterial functions following antibiotic…

Phase 2b Trial of MS1819, Yeast-based EPI for CF, Fully Enrolled

AzurRx BioPharma announced that its Phase 2b trial evaluating the safety and efficacy of MS1819 in treating exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) patients is fully enrolled. Thirty adults with CF are taking part in the OPTION 2 study (NCT04375878) comparing MS1819 with the current standard…

CF Foundation’s Impact Grant Program Benefits Communities

One need look no further than the name of the Cystic Fibrosis Foundation‘s Impact Grant program to figure out what it does — helping those affected by cystic fibrosis (CF) serve their disease community in creative ways that matter. The CF Foundation is currently accepting applications for the 2021 award…